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Aims We evaluated coronary artery disease (CAD) extent, severity, and major adverse cardiac events (MACEs) in never, past,
and current smokers undergoing coronary CT angiography (CCTA).
Methods
and results
We evaluated 9456 patients (57.1+ 12.3 years, 55.5% male) without known CAD (1588 current smokers; 2183 past
smokers who quit ≥3 months before CCTA; and 5685 never smokers). By risk-adjusted Cox proportional-hazards
models, we related smoking status to MACE (all-cause death or non-fatal myocardial infarction). We further performed
1:1:1 propensity matching for 1000 in each group evaluate event risk among individuals with similar age, gender, CAD risk
factors, and symptom presentation. During a mean follow-up of 2.8+1.9 years, 297 MACE occurred. Compared with
never smokers, current and past smokers had greater atherosclerotic burden including extent of plaque defined as seg-
ments with any plaque (2.1+ 2.8 vs. 2.6+3.2 vs. 3.1+3.3, P, 0.0001) and prevalence of obstructive CAD [1-vessel
disease (VD): 10.6% vs. 14.9% vs. 15.2%, P, 0.001; 2-VD: 4.4% vs. 6.1% vs. 6.2%, P ¼ 0.001; 3-VD: 3.1% vs. 5.2% vs. 4.3%,
P, 0.001]. Compared with never smokers, current smokers experienced higher MACE risk [hazard ratio (HR) 1.9, 95%
confidence interval (CI) 1.4–2.6, P, 0.001], while past smokers did not (HR 1.2, 95% CI 0.8–1.6, P ¼ 0.35). Among
matched individuals, current smokers had higher MACE risk (HR 2.6, 95% CI 1.6–4.2, P, 0.001), while past smokers
did not (HR 1.3, 95% CI 0.7–2.4, P ¼ 0.39). Similar findings were observed for risk of all-cause death.
Conclusion Among patients without known CAD undergoing CCTA, current and past smokers had increased burden of atheroscler-
osis compared with never smokers; however, risk of MACE was heightened only in current smokers.
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Clinical Perspective
Although smoking is an established risk factor for major cardiac adverse events (MACE), the relative risk of current smoking vs. past smoking is
less well studied. By using coronary CT angiography, our findings showed that when compared with never smokers, past smokers had
increased plaque similar to current smokers; however, compared with never smokers, higher MACE risk was observed only in current
smokers.
Introduction
Smoking is a major risk factor for coronary artery disease (CAD) and
risk of future major adverse cardiac events (MACEs).1– 6 While the
increased in risk of events applies to current smokers, several previ-
ous studies have shown that individuals who have quit smoking have
risk of future MACE that is similar to individuals who have never
smoked.3,4 The underlying pathophysiology explaining why event
rates do not remain elevated in individuals who have quit smoking
is not well understood.
Coronary CT angiography (CCTA) has emerged as a non-invasive
method to identify the presence, extent, severity, and type of coron-
ary artery plaque.7 –9 A large number of prognostic studies have
shown that the degree of coronary atherosclerosis identified by
CCTA is strongly predictive of subsequent cardiac events across a
broad spectrum of clinical settings.7,8 To date, the relationship
between smoking, CCTA findings, and subsequent MACE events
has not been evaluated. The purpose of this study is to examine
whether there is a difference in the presence, extent, severity of
CAD as well as plaque type by CCTA to explore the relationships
of these CADmeasurements to the riskof future MACE and all-cause
death in patients who never smoked, past, and current smokers.
Methods
Study population
We studied 9456 patients (mean age 57.1+12.3 years, 55.5% male)
without known CADfrompatients enrolled in the CONFIRM (Coronary
CT Angiography Evaluation for Clinical Outcomes: An International
Multicenter) registry10 whose smoking status was known. Of the
27 125 patients in the CONFIRM registry, the following patients were se-
quentially excluded fromthis study: those lacking smoking status informa-
tion (n ¼ 11 289), known CAD [prior myocardial infarction (MI) and
prior revascularization, n ¼ 1665], and lacking MACE follow-up (n ¼
4714). Patients were referred by physicians to CCTA for clinical
reasons, including both asymptomatic and symptomatic patients. Patients
were classified as never smokers [5685 (60%)], past smokers—indivi-
duals who quit smoking ≥3 months prior to CCTA [2183 (23%)], and
current smokers—individuals who currently smoked or quit ,3
months prior CCTA [1588 (17%)] as previously described.7 Each partici-
pating institution obtained Institutional Review Board approval.
Pre-scan risk factor assessment
As previously described, clinical CAD risk factors including smoking
history, hypertension, dyslipidemia, diabetes, and family history were col-
lected prior to the CCTA examination by direct patient interview by a
physician or nurse research coordinator and/or by standardized site
questionnaires.10 Chest symptom status at the time of CCTA was
categorized as asymptomatic, non-cardiac, atypical, typical chest pain,
and dyspnoea as previously described.11 –13
Imaging analysis
Coronary CTangiography was performed in each institution using 64 slice
or greater CT scanners.7,10 A modified 16-segment American Heart
Associationcoronary treemodelwasused todetectplaques. Plaquecom-
position (presence, severity stenosis, number, and characteristics) on
CCTAwasevaluatedbyexperienced level III equivalent readers in accord-
ancewithSCCTguideline.14 Coronaryplaquewas identifiedanyhyper-or
hypodense structure distinct from the lumen and.1 mm2 in size. Coron-
ary artery disease severity was classified for three groups: none (0%
luminal stenosis), non-obstructive (1–49% luminal stenosis), and ob-
structive stenosis (≥50% luminal stenosis), which was sub-classified as
1-vessel disease (VD), 2-VD, and 3-VD (including left main disease). For
measure of CAD extent, a segment involvement score (SIS) was
defined as the total number of coronary artery segments with any
plaque.8 The extent of CAD was classified for three groups: SIS with 0,
1–5 and .5 in accordance as previously described.8 Non-calcified
plaque (NCP) [containing no calcification], partially calcified plaque
(PCP) [containing both of calcification and NCP], or calcified plaque
(CP) [containing only calcification] was recoded as plaque characteristics.
Patient follow-up
As reported previously,10 the primary outcomes were assessed at each
institution by direct interview, telephone contact, review of medical
records, or using a mailed standardized questionnaire. In the USA, all-
cause mortality was additionally searched by the Social Security Death
Index. Major adverse cardiac event was defined as all-cause death or non-
fatal MI. Myocardial infarction was defined by site physicians in accord-
ance with ACC/AHA guideline and the World Health Organization
Universal Definition of Myocardial Infarction.15,16
Statistical analysis
Continuous variables were expressed as the mean+ SD. The Wilcoxon
rank-sum test was used to conduct intergroup comparisons among
never, past, and current smoker groups. Categorical variables were com-
paredusingPearsonx2 tests.Anone-way ANOVAor theKruskal–Wallis
test was used to conduct intergroup comparisons among never, past, and
current smoking groups.
The relationship of smoking status to the endpoints of time to MACE
or all-cause death was examined using risk-adjusted Cox proportional-
hazards models, the latter adjusted for age, sex, all other CAD risk
factors (hypertension, dyslipidemia, diabetes, family history of early
CAD), all chest symptoms (non-anginal, atypical, typical chest pain, and
dyspnoea), presence of obstructive CAD (≥50% stenosis), and SIS.
Event rates were compared using the log-rank test. Also we generated
MACE or all-cause-death-free survival curves among the never, past,
and current smokers using Cox proportional-hazards models adjusting
for the same variables within each stratum of smoking status. In addition,
CAD stenosis severity (normal, non-obstructive, and obstructive CAD)
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and extent (SIS 0, 1–5, and .5) were assessed among never, past, and
current smoking groups in relation to MACE by Cox proportional-
hazards models adjusted for age, gender, hypertension, diabetes, dyslipi-
demia, family history, and all chest symptoms.
Because of the potential differences of age, gender, other risk factors,
and symptom presentations among the three smoking groups,MACE and
death risk were also analysed in subgroups of the three smoking categor-
ies matched for age, gender, the other CAD risk factors, and the chest
symptoms using propensity scores, where the propensity score was
the resulting probabilities of a logistic regression model predicting
being among never, past, and current smoking groups with age, gender,
other CAD risk factors, and the chest symptoms as predictors. The
resulting propensity score was then applied 1:1:1 to match every never
smoker to a corresponding past or current smoker using a Mahalanobis
nearest-neighbour matching algorithm.17 This matching resulted in 1000
never smokers being matched to 1000 past or 1000 current smokers, re-
spectively. Multivariable Cox proportional-hazards models were used to
assess the relationship of smoking status to an endpoint of time to MACE
or all-cause death after adjusting for age, gender, other CAD risk factors,
chest symptoms, presence of obstructive CAD, and SIS.
Scaled Schoenfeld residuals were used to verify the assumption of pro-
portional hazards of the Coxmodels.18 A hazard ratio (HR) and 95% con-
fidence interval (CI) were calculated from the Cox models. All statistical
calculations were carried out using STATA (Version 12, StataCorp LP,
College Station, TX, USA) for Windows.
Results
Overall population
Baseline characteristics
The baseline characteristics among never, past, and current smokers
are shown in Table 1. There were multiple differences between
the groups. Notably, compared with never smokers, past and
current smokers were predominantly male and more commonly
symptomatic. Never and past smokers were older than current
smokers (57.4+ 12.6 years vs. 59.3+11.0 years vs. 53.0+ 11.9
years, P, 0.0001). Past smokers had a greater prevalence of hyper-
tension, diabetes, and dyslipidemia compared with never or current
smokers. More current smokers had a family history of premature
CAD and were male than the never and past smokers (Table 1).
Coronary artery disease extent, severity, and plaque type
Coronary artery disease extent, severity, and plaque type are pre-
sented in Table 2. Regarding CAD extent as defined by SIS, compared
with never smokers, past and current smokers had greater extent of
coronary plaque, and past smokers had more plaque than current
smokers. Regarding plaque severity, compared with never
smokers, past and current smokers had a greater prevalence of ob-
structive CAD and the obstructive CAD categories including 1-, 2-,
and 3-VD. Past smokerspossessed more non-obstructiveCADcom-
pared with never and current smokers. The absence of plaque was
most frequent in the never smokers. Non-calcified plaque and PCP
were more prevalent among past and current smokers compared
with never smokers.
Rates and adjusted risk of major adverse cardiac event
and death by smoking categories
At a mean follow-up of 2.8+ 1.9 years, 297 subjects experienced
MACE (3.1%). Major adverse cardiac event occurred more often in
current smokers compared with the past or never smokers (4.8%
vs. 2.9% vs. 2.8%, P, 0.001 for all); however, the MACE rates
were similar in the never and past smokers. With respect to all-cause
death (192 patients), a higher proportion of current smokers
died compared with past or never smokers (3.0% vs. 1.8% vs. 1.9%,
P ¼ 0.02 for all); however, the death rates were similar in never
and past smokers (Table 3). In a multivariable Cox proportional-
hazards model, adjusting for age, sex, hypertension, diabetes, dyslipi-
demia, family history, all symptoms, coronary stenosis severity
≥50%, and SIS, current smokers experienced higher MACE risk com-
paredwith never smokers (HR 1.9, 95% CI 1.4–2.6, P, 0.001), while
past smokers did not (HR 1.2, 95% CI 0.8–1.6, P ¼ 0.35). Similarly,
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Table 1 Study population among never, past, and current smokers (n 5 9456)
Never (n 5 5685) Past (n5 2183) Current (n 5 1588) P-value for all
Age 57.4+12.6 59.3+11.0† 53.0+11.9†,* ,0.0001
Male gender 2951 (51.9) 1287 (59.0)† 1006 (63.4)†,** ,0.001
Hypertension 2629 (46.7) 1116 (51.7)† 721 (45.8)* ,0.001
Diabetes 667 (11.8) 297 (13.6)‡ 160 (10.1)** 0.004
Dyslipidemia 2853 (50.8) 1262 (58.5)† 823 (52.2)* ,0.001
Family history 2119 (38.3) 808 (38.5) 687 (44.8)†,* ,0.001
Chest symptom
Asymptomatic 1812 (32.1) 621 (28.8)‡ 416 (26.7)†,* ,0.001
Non-cardiac 626 (11.1) 242 (11.2) 230 (14.8)†,** ,0.001
Atypical 2270 (40.3) 768 (35.7)† 657 (42.1)* ,0.001
Typical 518 (9.2) 224 (10.4) 154 (9.9) 0.24
Dyspnoea 412 (7.3) 299 (13.9)† 102 (6.5)* ,0.001
Non-cardiac, atypical, and typical refer to chest pain types.
†P, 0.001 and ‡P, 0.05 for the comparison with never smoking group.
*P, 0.001 and **P, 0.05 for the comparison with past smoking group.
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after adjustment for the same factors, the risk of death was higher in
the current smokers (HR 2.0, 95% CI 1.4–2.9, P, 0.001) than in the
never smokers, but not in the past smokers (HR 1.2, 95% CI 0.8–1.8,
P ¼ 0.31) (Table 3). Major adverse cardiac event or all-cause-death-
free survival curves similarly showed increased risk of MACE or
death only in current smokers (Figure 1A and B).
Major adverse cardiac event risk assessed by smoking
categories and coronary plaque extent and severity
Figure 2A demonstrates results of risk-adjusted Cox proportional-
hazards models for MACE by SIS category among never, past, and
current smokers. Compared with the never smokers with SIS 0,
past (HR 1.0, 95% CI 0.4–2.4, P ¼ 0.996) or current smokers with
SIS 0 (HR 1.7, 95% CI 0.8–2.4, P ¼ 0.20) did not have increased
MACE risk. In the SIS 1–5 category, the MACE risk was higher than
that of the patients with SIS 0 in all smoking categories. While the
risk among past smokers (HR 2.0, 95% CI 1.2–3.3, P ¼ 0.01) was
slightly higher than that of the never smokers (HR 1.7, 95% CI,
1.1–2.5, P ¼ 0.02), it was much higher in the current smokers (HR
3.1, 95% CI, 1.9–5.2, P, 0.001). In the SIS .5 category, the
MACE risk was further increased in all smoking categories. Of note,
as with the SIS 1–5 category, the risk was slightly higher in the past
smokers (HR 2.7, 95% CI 1.6–4.8, P, 0.001) than in the never
smokers (HR 2.3, 95% CI 1.4–3.7, P ¼ 0.001), but was much higher
in the current smokers (HR 5.1, 95% CI 30–8.6, P, 0.001).
Figure 2B demonstrates results of risk-adjusted Cox proportional-
hazards models for MACE by normal, non-obstructive, and obstruct-
ive CAD among never, past, and current smokers. The MACE risk
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Table 2 Coronary artery plaque extent, severity, and characteristics among never, past, and current smokers (n 5 9456)
Never (n5 5685) Past (n 5 2183) Current (n 5 1588) P-value
Vessel disease (%)
Normal 2586 (45.49) 671 (30.74)† 625 (39.36)†,* ,0.001
Non-obstructive disease 2072 (36.45) 952 (43.61)† 548 (34.51)* ,0.001
Obstructive disease 1027 (18.07) 560 (25.65)† 415 (26.13)† ,0.001
1-vessel 601 (10.57) 331 (15.16)‡ 236 (14.86)† ,0.001
2-vessel 250 (4.40) 136 (6.23)‡ 97 (6.11)‡ 0.001
3-vessel 176 (3.10) 93 (4.26)‡ 82 (5.16)† ,0.001
SIS (mean+ SD) 2.1+2.8 3.1+3.3‡ 2.6+3.2‡,** ,0.0001
SIS 1–5 2309 (40.62) 1008 (46.17)† 659 (41.50)* ,0.001
SIS .5 790 (13.90)† 504 (23.09)† 304 (19.14)** ,0.001
Prevalence of any plaque type (%)
NCP 975 (17.2) 525 (24.1)† 357 (22.5)† ,0.001
PCP 1185 (20.8) 668 (30.6)† 508 (32.0)† ,0.001
CP 1280 (22.5) 663 (30.4)† 388 (24.4)* ,0.001
SIS, segment involvement score; NCP, non-calcified plaque; PCP, partially calcified plaque; CP, calcified plaque.
†P, 0.001 and ‡P, 0.05 for the comparison with never smoking group.
*P, 0.001 and **P, 0.05 for the comparison with past smoking group.
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Table 3 Rates and adjusted Cox proportional-hazard risk of major adverse cardiac event and all-cause death among
whole population (n5 9456)
Never (n 5 5685) Past (n5 2183) Current (n 5 1588) P-value
Rates of MACE and all-cause death (n, %)
MACE 158 (2.8) 63 (2.9) 76 (4.8)†,** ,0.001
All-cause death 106 (1.9) 39 (1.8) 47 (3.0)‡,** 0.02
HR (95% CI) HR (95% CI) HR (95% CI)
Adjusted risk of MACE and all-cause death
MACE 1.0 (reference) 1.2 (0.8–1.6) 1.9 (1.4–2.6)† –
All-cause death 1.0 (reference) 1.2 (0.8–1.8) 2.0 (1.4–2.9)‡ –
MACE, major adverse cardiac event.
†P, 0.001 and ‡P, 0.05 for the comparison with never smoking group.
*P, 0.001 and **P, 0.05 for the comparison with past smoking group.
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among never smokers with non-obstructive CAD tended to be
higher than that of those with normal CCTA (HR 1.5, 95% CI 0.9–
2.3, P ¼ 0.08). This risk was significantly higher in past smokers (HR
2.0, 95% CI 1.2–3.5, P ¼ 0.008) and was even greater in current
smokers (HR 2.6, 95% CI 1.5–4.6, P ¼ 0.001). Subjects with ob-
structive CAD experienced higher MACE rates compared with
never smokers with normal CCTA regardless of smoking status
(never: HR 2.5, 95% CI 1.6–3.9, P, 0.001; past: HR 2.6, 95% CI
1.5–4.5, P ¼ 0.001; current: HR 5.2, 95% CI 3.2–8.5, P, 0.001).
Matched population
Baseline characteristics
The matching was successful with no overall significant differences
between the three groups in all variables for which the match was
considered. Past smokers had more diabetes compared with never
smokers (11.4% vs. 8.6%, P ¼ 0.04) (Table 4).
Coronary artery disease extent, severity, and plaque type
Both current and past smokers had higher SIS and greater prevalence
of all plaque types, compared with never smokers (Table 5). Past
smokers more commonly had non-obstructive CAD, and current
smokers had a greater prevalence of obstructive CAD, compared
with never smokers. Current smokers had a higher prevalence of
PCP compared with past and never smokers.
Rates and adjusted risk of major adverse cardiac event
and death
A higher proportion of current smokers experienced MACE (6.9%,
P, 0.001 vs. both other groups); however, MACE occurred in a
similar proportion of the past smokers and the never smokers
(2.4% vs. 2.2%, P ¼ 0.77). Current smokers had a higher rate of
death than the other two groups (4.2%, P, 0.001 vs. both other
groups); however, the death rate was not different between the
past and never smokers (1.1% vs. 1.4%, P ¼ 0.55) (Table 6). In multi-
variable Cox proportional analysis, adjusting for age, sex, hyperten-
sion, diabetes, dyslipidemia, family history, all symptoms, coronary
stenosis severity ≥50%, and SIS, current smokers experienced a
higher risk of MACE compared with never smokers (HR 2.6, 95%
CI 1.6–4.2, P, 0.001), but past smokers did not (HR 1.3, 95% CI
0.7–2.4, P ¼ 0.39). Similarly, after adjustment for the same factors,
the risk of death was higher in current smokers (HR 2.5, 95% CI
1.3–4.6, P ¼ 0.005), compared with the never smokers, while it
was not higher in the past smokers (HR 1.1, 95% CI 0.5–2.6, P ¼
0.75) (Table 6). Major adverse cardiac event or all-cause-death-free
survival curves showed increased risk of MACE or death only in
current smokers (Figure 3A and B).
Discussion
This report from the CONFIRM registry is the first study to examine
the relationshipbetweenthe extent and severityofCADbycoronary
CT angiography, smoking status, and the risk of subsequent MACE
events. We demonstrated that past and current smokers had
similar extent and severity of coronary atherosclerosis, which was
greater than that of never smokers; however, only current smokers
had greater risk-adjusted cardiac events. We observed similar find-
ings with respect to the extent and severity of CAD and cardiac
events in a subgroup that was propensity matched to achieve similar-
ities of age, gender, other CAD risk factors, and chest symptoms. In
the matched population, compared with never smokers, both past
and current smokers had a higher prevalence of non-obstructive or
obstructive CAD and greater extent of CAD; however, only
current smokers experienced a significantly higher MACE risk. This
risk among past smokers was slightly but not significantly higher
than that of never smokers.
Numerous prior investigators have observed that smoking was
associated with the atherosclerosis formation, progression, and
future MACE risk.1– 6,19– 21 Active smoking is strongly associated
with endothelial dysfunction and coronary thrombosis.19,22– 29 In
current smokers, the impaired release of tissue plasminogen activa-
tor antigen and reduced coronary blood flow has been reported
compared with non-smokers.19,22 Further, platelet aggregation is
increased among active smokers.24–27 These factors, along with
the increased amounts of coronary atherosclerosis, may be respon-
sible for the reported increase in risk of acute coronary throm-
bosis22,24– 27 and potentially contribute to the association of
current smokers with higher MACE risk noted in the present study.
Our finding that future MACE risk was similar among never and
past smokers is concordant with numerous prior studies.3,4 Regard-
ing the angiographic correlates of these observations, previous
studies using invasive coronary angiography have assessed the rela-
tionship of the extent CAD and MACE risk according to smoking
Figure 1 (A) Risk-adjusted event-free survival curves for major
adverse cardiac event among never, past, and current smokers
(n ¼ 9456). (B) Risk-adjusted event-free survival curves for all-
cause death among never, past, and current smokers (n ¼ 9456).
Adjusted for age, gender, symptoms, dyslipidemia, hypertension,
diabetes, family history, all chest symptoms, segment involvement
scores, and stenosis severity ≥50%. MACE, major adverse cardiac
events.
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status.5,6 As was found in the present study, these prior reports
showed that smoking cessation was associated with reduced risk of
death, MI, or revascularization regardless of the angiographic
extent of CAD.
The potential mechanism of the similar risks of events in past and
never smokers despite the increased burden of atherosclerosis is
unclear. It may be due to improvement of endothelial function,28,29
decreased fibrinogen and inflammatory markers30 that have been
associated with smoking cessation, or some other biologic protective
effect reducing the riskof coronaryartery plaque rupture. As another
potential contributing factor, smokers who successfully quit may also
have adopted other heart-healthy lifestyle behaviours such as diet,
Figure 2 (A) Risk-adjusted Cox proportional-hazards models for major adverse cardiac event by SIS 0, 1–5, and .5 among never, past, and
current smokers (n ¼ 9456). (B) Risk-adjusted Cox proportional-hazards models for major adverse cardiac event by normal, non-obstructive,
and obstructive CAD among never, past, and current smokers (n ¼ 9456). Adjusted for age, sex, symptoms, dyslipidemia, hypertension, diabetes,
family history, and all chest symptoms. MACE, major adverse cardiac events; SIS, segment involvement score; CAD, coronary artery disease.
*P, 0.001 and **P, 0.05 for the comparison with never smokers with normal coronary CT angiography.
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exercise, and the use of medications that reduce risk of coronary
artery event to a greater degree than the never smokers.
Large observational studies have demonstrated that the age of
patients who stopped smoking was an important factor in explaining
known decrease in mortality risk associated with smoking cessa-
tion.31,32 In a study of 34 439 men followed up to 50 years,31 patients
who quit smoking before 30 years of age avoided most all of mortality
risk, whereas reduction in mortality risk associated with smoking ces-
sationdecreasedprogressivelyas theage at timeofquitting increased.
Similarly, a study of 1.2 million women resurveyed 3–8 years after
initial recording of smoking status,32 demonstrated that cessation
of smoking before age 30 avoided almost all of the excess mortality
caused by smoking, and that the mortality benefit of quitting
smoking compared with not quitting decreased progressively as the
age at the time of smoking cessation increased. Other studies have
also demonstrated that there is decreased incidence of coronary
artery calcification as a marker of atherosclerosis in past smokers
compared with current smokers and that the degree of this
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Table 4 Matched (1:1:1) population among never, past, and current smokers (n5 3000)
Never (n 5 1000) Past (n 5 1000) Current (n5 1000) P-value
Age 53.4+11.6 54.1+10.8 53.3+12.0 0.28
Male gender 636 (63.6) 620 (62.0) 632 (63.2) 0.74
Hypertension 446 (44.6) 471 (47.1) 453 (45.3) 0.51
Diabetes 86 (8.6) 114 (11.4)‡ 105 (10.5) 0.11
Dyslipidemia 516 (51.6) 537 (53.7) 529 (52.9) 0.64
Family history 481 (48.1) 455 (45.5) 468 (46.8) 0.51
Chest symptom
Asymptomatic 261 (26.1) 274 (27.4) 267 (26.7) 0.81
Non-cardiac 141 (14.1) 142 (14.2) 143 (14.3) 0.99
Atypical 455 (45.5) 420 (42.0) 422 (42.2) 0.21
Typical 95 (9.5) 112 (11.2) 108 (10.8) 0.43
Dyspnoea 48 (4.8) 52 (5.2) 60 (6.0) 0.48
Non-cardiac, atypical, and typical refer to chest pain types.
†P, 0.001 and ‡P, 0.05 for the comparison with never smoking group.
*P, 0.001 and **P, 0.05 for the comparison with past smoking group.
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Table 5 Coronary artery plaque extent, severity, and characteristics among matched never, past, and current smokers
(n 5 3000)
Never (n5 1000) Past (n 5 1000) Current (n5 1000) P-value
Vessel disease (%)
Normal 472 (47.2) 397 (39.7)‡ 387 (38.7)† ,0.001
Non-obstructive disease 338 (33.8) 389 (38.9)‡ 341 (34.1)** 0.03
Obstructive disease 190 (19.0) 214 (21.4) 272 (27.2)†,** ,0.001
1-vessel 101 (10.1) 132 (13.2)‡ 155 (15.5)† 0.001
2-vessel 50 (5.0) 51 (5.1) 63 (6.3) 0.36
3-vessel 39 (3.9) 31 (3.1) 54 (5.4)** 0.03
SIS (mean+ SD) 2.0+2.8 2.5+3.1† 2.6+3.1† ,0.0001
SIS 1–5 398 (39.8) 425 (42.5) 425 (42.5) 0.37
SIS .5 130 (13.0) 178 (17.8)‡ 188 (18.8)† 0.001
Prevalence of any plaque type (%)
NCP 176 (17.6) 233 (23.3)‡ 231 (23.1)‡ 0.002
PCP 195 (19.5) 274 (27.4)† 335 (33.5)†,** ,0.001
CP 193 (19.3) 250 (25.0)‡ 258 (25.8)‡ 0.001
SIS, segment involvement score; NCP, non-calcified plaque; PCP, partially calcified plaque; CP, calcified plaque.
†P, 0.001 and ‡P, 0.05 for the comparison with never smoking group.
*P, 0.001 and **P, 0.05 for the comparison with past smoking group.
Current but not past smoking increases the risk of cardiac events 1037
decreased incidence is age related.33,34 In our study, the risk of MACE
events in the past smokers appeared to improve over time in our un-
matched population. The results in our matched population,
however, suggest that the risk of MACE events is similar between
past and never smokers early after testing. Whether the difference
in our matched and unmatched populations in this regard is related
to increased risk factor burden in the past smokers of the unmatched
population compared with the never smokers or to other factors
cannot be determined from our data. We did not have information
regarding the age at which smoking was stopped in the past
smokers of this study.
The study has several limitations. The study includes patients
undergoing clinical indicated CCTA studies and whether the
present results can be extrapolated to population-based cohorts
remains unknown. The follow-up period was for an average of 2.8
years. The hazard ratio for MACE was slightly but not significantly
higher in past smokers than in never smokers (1.2 and 1.3 in the
whole and the matched populations, respectively). A longer follow-
up with more clinical events is needed to determine whether there
is a difference in the event rates in these two groups. From the
CONFIRM registry, only patients in whom smoking status was
reported and follow-up for MACE was available were included.
Smoking information was limited to identification of patients who
were current, past, or never smokers. There was no information
regarding duration and amount of smoking, time interval from
smoking cessation to testing, or exposure to passive smoking, all of
which are associated with CAD and the future risk.21,31,32,35,36
There was no information regarding lifestyle behaviour in the
various groups.
Conclusion
Among patients without known CAD undergoing CCTA, current
and past smokers had increased burden of atherosclerosis compared
with never smokers; however, the risk of death and MACE was heigh-
tened only in the current smokers.
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Table 6 Rates and adjusted Cox proportional-hazard risk of major adverse cardiac event and all-cause death
among whole population (n 5 3000)
Never (n 5 1000) Past (n5 1000) Current (n 5 1000) P-value
Rates of MACE and all-cause death (n, %)
MACE 22 (2.2) 24 (2.4) 69 (6.9)†,* ,0.001
All-cause death 14 (1.4) 11 (1.1) 42 (4.2)†,* ,0.001
HR (95% CI) HR (95% CI) HR (95% CI)
Adjusted risk of MACE and all-cause death
MACE 1.0 (reference) 1.3 (0.7–2.4) 2.6 (1.6–4.2)† –
All-cause death 1.0 (reference) 1.1 (0.5–2.6) 2.5 (1.3–4.6)‡ –
MACE, major adverse cardiac event.
†P, 0.001 and ‡P, 0.05 for the comparison with never smoking group.
*P, 0.001 and **P, 0.05 for the comparison with past smoking group.
Figure 3 (A) Risk-adjusted event-free survival curves for major
adverse cardiac event among matched never, past, and current
smokers (n ¼ 3000). (B) Risk-adjusted event-free survival curves
for all-cause death among matched never, past, and current
smokers (n ¼ 3000). Adjusted for age, gender, symptoms, dyslipi-
demia, hypertension, diabetes, family history, all chest symptoms,
segment involvement scores, and stenosis severity ≥50%. Abbre-
viations as in Figure 1.
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Serial imaging observations of vascular healing in a denervation-induced
renal artery dissection
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A 75-year-old woman underwent bilateral renal
denervation with an ultrasound-based balloon
denervation system (ParadiseTM; Recor Medical,
Palo Alto, CA, USA) due to resistant hypertension.
The procedure was successfully completed
without clinical adverse events; however, the post-
procedural right renal artery angiogram showed
non-flow limiting lumen irregularities, associated
with micro-thrombi and dissections with intramural
hematoma formation by optical coherence tomog-
raphy (OCT). No further treatment was performed
and the patient was discharged on aspirin for 1
month. Six-month follow-up magnetic resonance
angiography (MRA) showed no signs of stenosis.
At 1 year, severe refractory hypertension persisted (mean office 193/93 mmHg) and the patient suffered a cerebrovascular accident. In
view of the persistent elevated blood pressure, a repeat procedure was performed 19 months after the baseline procedure. Prior to
the repeat procedure, OCT was performed in the right renal artery demonstrating no evidence of vascular trauma with complete
healing of the dissections and resolution of the hematoma.
Although small dissections and micro-thrombi have been reported as direct vascular consequences of renal denervation with several
different devices, their clinical significance remains unclear. We present for the first time the follow-up of a denervation-induced dissection
showing a completed healing process with no evidence of persistent vascular trauma or development of stenosis.
Angiographic andoptical coherence tomography (OCT) images fromthe right renal artery from pre-denervation, post-denervation, and
at the repeat procedure. Follow-up angiography demonstrates the resolution of lumen irregularities, while OCT images disclose the com-
plete healing of dissections and intramural hematoma. White arrow, dissection; yellow arrow, thrombus; cross, hematoma.
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